Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Alvarez

Showing results (541-550 of 644) with videos related to

Pageof 65
Sort By:
Clinical Genetics|September 9, 2015
A Mayan founder mutation is a common cause of deafness in GuatemalaC Carranza, I Menendez, M Herrera, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2008
Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatmentT Dejaegere, L Serneels, M K Schäfer, et al.
Developments in Biologicals|January 5, 2002
Viral latency--the papillomavirus modelT R Broker, G Jin, A Croom-Rivers, et al.
The Journal of Gene Medicine|April 15, 2003
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapyShannon D Barker, Candace J Coolidge, Anna Kanerva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trialR D Alvarez, M N Barnes, J Gomez-Navarro, et al.
Obstetrics and Gynecology|May 15, 2025
A Framework for Building Surgical Competence in the Practice of Gynecology: A Discussion From the 2024 American Gynecological & Obstetrical Society Annual MeetingRonald D Alvarez, Warner K Huh, AnnaMarie Connolly, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trialRonald D Alvarez, Michael G Conner, Heidi Weiss, et al.
Gynecologic Oncology|August 14, 2017
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group studyPremal H Thaker, William E Brady, Heather A Lankes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Gene Therapy|February 8, 2005
Evaluation of tumor-specific promoter activities in melanomaB Lu, S K Makhija, D M Nettelbeck, et al.
Pageof 65

Showing results (541-550 of 644) with videos related to

Sort By:
Pageof 65
Clinical Genetics|September 9, 2015
A Mayan founder mutation is a common cause of deafness in GuatemalaC Carranza, I Menendez, M Herrera, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2008
Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatmentT Dejaegere, L Serneels, M K Schäfer, et al.
Developments in Biologicals|January 5, 2002
Viral latency--the papillomavirus modelT R Broker, G Jin, A Croom-Rivers, et al.
The Journal of Gene Medicine|April 15, 2003
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapyShannon D Barker, Candace J Coolidge, Anna Kanerva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trialR D Alvarez, M N Barnes, J Gomez-Navarro, et al.
Obstetrics and Gynecology|May 15, 2025
A Framework for Building Surgical Competence in the Practice of Gynecology: A Discussion From the 2024 American Gynecological & Obstetrical Society Annual MeetingRonald D Alvarez, Warner K Huh, AnnaMarie Connolly, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trialRonald D Alvarez, Michael G Conner, Heidi Weiss, et al.
Gynecologic Oncology|August 14, 2017
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group studyPremal H Thaker, William E Brady, Heather A Lankes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Gene Therapy|February 8, 2005
Evaluation of tumor-specific promoter activities in melanomaB Lu, S K Makhija, D M Nettelbeck, et al.
Pageof 65